Cardiotoxicities in Patients Receiving BTKi

WithdrawnOBSERVATIONAL
0
Timeline

Start Date

May 31, 2024

Primary Completion Date

January 1, 2026

Study Completion Date

January 1, 2028

Conditions
Chronic Lymphocytic LeukemiaSmall Lymphocytic Lymphoma
Interventions
DIAGNOSTIC_TEST

Electrocardiogram

ECG to monitor electrical activities of the heart on each visit

DIAGNOSTIC_TEST

Echocardiogram

Echocardiogram at baseline and 6 months

DIAGNOSTIC_TEST

Cardiac magnetic resonance imaging

Cardiac MRI at baseline and 6 months

DEVICE

Mobile cardiac telemetry

Mobile cardiac telemetry at baseline and 6 months

DIAGNOSTIC_TEST

Blood pressure monitoring

Home blood pressure monitoring three times per week

DIAGNOSTIC_TEST

Blood draw

Blood draw at baseline, 3 and 6 months

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

AstraZeneca

INDUSTRY

lead

Dana-Farber Cancer Institute

OTHER